5-Fluorouracil/folinate/oxaliplatin (Eloxatin) (FLOX [FOLFOX] regimen), given continuously or intermittently, in combination with cetuximab (Erbitux), in first-line treatment of metastatic colorectal cancer. A phase III multicenter trial.

Trial Profile

5-Fluorouracil/folinate/oxaliplatin (Eloxatin) (FLOX [FOLFOX] regimen), given continuously or intermittently, in combination with cetuximab (Erbitux), in first-line treatment of metastatic colorectal cancer. A phase III multicenter trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms Nordic-VII
  • Most Recent Events

    • 11 Apr 2017 Results of final survival analyses and extended RAS data published in the British Journal of Cancer.
    • 04 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 12 Jul 2011 Denmark, Finland, Iceland and Norway reports trial status (completed) and Sweden reports trial status recruiting as by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top